81 completed, 17 terminated, 5 withdrawn, 4 active not recruiting. 62 Phase 1, 46 Phase 2, 9 Not applicable, 2 Phase 3.
Follow Recurrent Adult Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent Adult Acute Lymphoblastic Leukemia trials Research Report on Recurrent Adult Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Withdrawn | University of Washington | 2018-07-01 | 2018-11-14 | |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 55 | 2017-11-03 | 2024-04-10 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 33 | 2017-10-20 | 2026-06-30 |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Dasatinib, Laboratory Biomarker Analysis, Nivolumab - B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Northwestern University | 1 | 2017-08-17 | 2020-02-11 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2017-04-06 | 2025-03-03 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome - Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia | Phase 1 | Withdrawn | Northwestern University | 2016-08-01 | 2016-12-15 | |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil - Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome | Phase 1 | Terminated | Stanford University | 1 | 2016-02-01 | 2018-09-12 |
| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies radiation therapy, cyclophosphamide, anti-thymocyte globulin - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 1 | Completed | Sumithira Vasu | 33 | 2015-07-27 | 2023-09-21 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate - Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 31 | 2015-06-25 | 2025-06-22 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia cyclophosphamide, vincristine sulfate, prednisone - Acute Leukemias of Ambiguous Lineage, B-cell Adult Acute Lymphoblastic Leukemia | Phase 1 | Completed | SWOG Cancer Research Network | 50 | 2014-06-13 | 2023-05-03 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML etoposide, cyclophosphamide, total marrow irradiation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Active not recruiting | City of Hope Medical Center | 108 | 2014-05-12 | 2026-07-01 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2014-04-10 | 2024-03-12 |
| Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Ibrutinib, Laboratory Biomarker Analysis - Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2014-04-01 | 2017-01-16 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
Showing 20 of 108. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (108) · Leukemia, Myeloid, Acute (75) · Leukemia, Lymphocytic, Chronic, B-Cell (53) · Burkitt Lymphoma (51) · Congenital Abnormalities (49) · Lymphoma, Non-Hodgkin (48) · Lymphoma, Large B-Cell, Diffuse (46) · Lymphoma, Mantle-Cell (46) · Lymphoma, B-Cell, Marginal Zone (45) · Lymphoma, Follicular (45) · Blast Crisis (44) · Hodgkin Disease (41) · Lymphoma, Large-Cell, Immunoblastic (41) · Lymphoma, T-Cell, Cutaneous (38) · Mycosis Fungoides (37)
Hematologic Diseases (108) · Hemic and Lymphatic Diseases (108) · Immune System Diseases (108) · Immunoproliferative Disorders (108) · Leukemia (108) · Leukemia, Lymphoid (108) · Lymphatic Diseases (108) · Lymphoproliferative Disorders (108) · Neoplasms by Histologic Type (108) · Neoplasms (106) · Pathologic Processes (84) · Pathological Conditions, Signs and Symptoms (84) · Chronic Disease (83) · Disease Attributes (83) · Leukemia, Myeloid (77)
Peripheral Blood Stem Cell Transplantation (27) · Whole-Body Irradiation (24) · fludarabine phosphate (24) · Mycophenolic Acid (22) · Cyclophosphamide (16) · Cyclosporine (15) · Tacrolimus (13) · Methotrexate (9) · merphos (9) · Cytarabine (8) · Transplantation (8) · Cyclosporins (7) · Rituximab (7) · Busulfan (6) · Vincristine (6)
National Cancer Institute (NCI) (45) · Fred Hutchinson Cancer Center (28) · City of Hope Medical Center (5) · Roswell Park Cancer Institute (5) · Wake Forest University Health Sciences (3) · Case Comprehensive Cancer Center (2) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · Mayo Clinic (2) · Northwestern University (2) · Stanford University (2) · University of Chicago (2) · Albert Einstein College of Medicine (1) · Children's Oncology Group (1) · Martin, Paul (1) · Robert Lowsky (1)
United States (105) · Italy (8) · Germany (7) · Canada (4) · Australia (2) · Puerto Rico (2) · Denmark (1) · New Zealand (1) · Switzerland (1)
Brenda Sandmaier (8) · David Maloney (5) · Francis Giles (3) · Ivana Gojo (3) · Jorge Cortes (3) · Marco Mielcarek (3) · Paul Martin (3) · B. Smith (2) · Farhad Ravandi-Kashani (2) · George Chen (2) · George Georges (2) · Hongtao Liu (2) · Jordan Gauthier (2) · Judith Karp (2) · Olatoyosi Odenike (2)
PMID 32499241, PMID 34515338, PMID 18974373, PMID 20460644, PMID 20952518, PMID 21239698, PMID 21508120, PMID 21791475, PMID 22259028, PMID 22448921, PMID 23256542, PMID 23443507, PMID 23660685, PMID 24474568, PMID 25085357, PMID 26213141, PMID 26764356, PMID 26853648, PMID 27111235, PMID 28314788, PMID 28419486, PMID 28817727, PMID 29038338, PMID 29572391, PMID 29618479, PMID 30562587, PMID 30728140, PMID 30729531, PMID 30782611, PMID 30957229, PMID 31481800, PMID 31582553, PMID 31617432, PMID 31648294, PMID 32628342, PMID 32929049, PMID 32967009, PMID 33420905, PMID 34563945, PMID 34666344, PMID 34889384, PMID 35007144, PMID 36282798, PMID 37774014, PMID 37960985, PMID 39333103, PMID 39820359, PMID 42150590, PMID 42389828
P30CA015704 (19), P01CA018029 (11), U01CA070095 (9), U01CA062461 (7), P01CA078902 (5), U01CA062491 (4), U01CA062505 (4), U01CA076576 (4), N01CM62202 (3), P30CA006973 (3), P30CA016672 (3), U01CA062502 (3), U10CA032102 (3), U10CA180888 (3), P01CA044991 (2)